Regenerative Research Foundation

The phase 1/2a clinical trial completed its first cohort of patients during calendar year 2024. The study continues to recruit subjects and at in discussions with a potential second clinical site which will expand the subject recruitment population. The principal investigator, dr. Jeffrey stern, presented study results as an invited speaker at the national eye institute. The institute was also successful in obtaining regenerative medicine advanced therapy (rmat) designation from the fda for its cell-based therapy.

The alzheimer's disease and related dementias research program continued its mission to expand the understanding and development of a potential treatment for these neurodegenerative diseases. The institute serves as the lead organization for a consortium of institutions and investigators focused on identifying genes associated with the development of dementia. The national institutes of health and several public charities support this undertaking both programmatically and financially. The foundation is seeking biotech partnerships to support research and development of a promising neurodegenerative disease treatment.